reports
HCI Reports Fourth Quarter and Full Year 2025 Results
HCI Reports Fourth Quarter and Full Year 2025 Results Fourth Quarter Pre-Tax Income of $144 million and Diluted EPS of $7.25Full Year 2025 Pre-Tax Income of $429 million and Diluted EPS of $22.72Gross Loss Ratio of 15.6% for the fourth quarter and 19.6% for the full year 2025 TAMPA, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- HCI Group, Inc. (NYSE:HCI), reported pre-tax income of $144 million and net income of $108 million in the fourth quarter of 2025 compared with pre-tax income of $6 million and net income of $4 million in the fourth quarter of 2024. Net income after noncontrolling intere...
- Jonathan Moreland
TYL TYLER TECHNOLOGIES INC.
SBCF SEACOAST BANKING CORPORATION OF FLORIDA
HTGC HERCULES CAPITAL INC.
HCI HCI GROUP INC.
CGNX COGNEX CORPORATION
CAR AVIS BUDGET GROUP INC.
TZOO TRAVELZOO
KYN KAYNE ANDERSON MLP INVESTMENT CO.
ITIC INVESTORS TITLE CO.
HLNE HAMILTON LANE INCORPORATED CLASS A
SSTI SHOTSPOTTER
UBER UBER TECHNOLOGIES INC.
NBR NABORS INDUSTRIES LTD.
RBLX ROBLOX
BLCO BAUSCH + LOMB CORP
CVI CVR ENERGY
GF INC.
THE NEW GERMANY FUND
INC.
- Jonathan Moreland
TYL TYLER TECHNOLOGIES INC.
SBCF SEACOAST BANKING CORPORATION OF FLORIDA
HTGC HERCULES CAPITAL INC.
HCI HCI GROUP INC.
CGNX COGNEX CORPORATION
CAR AVIS BUDGET GROUP INC.
TZOO TRAVELZOO
KYN KAYNE ANDERSON MLP INVESTMENT CO.
ITIC INVESTORS TITLE CO.
HLNE HAMILTON LANE INCORPORATED CLASS A
SSTI SHOTSPOTTER
UBER UBER TECHNOLOGIES INC.
NBR NABORS INDUSTRIES LTD.
RBLX ROBLOX
BLCO BAUSCH + LOMB CORP
CVI CVR ENERGY
GF INC.
THE NEW GERMANY FUND
INC.
Donegal Group Inc. Announces Fourth Quarter and Full Year 2025 Results
Donegal Group Inc. Announces Fourth Quarter and Full Year 2025 Results MARIETTA, Pa., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Donegal Group Inc. (NASDAQ:DGICA) and (NASDAQ:DGICB) today reported its financial results for the fourth quarter and full year ended December 31, 2025. Significant items for fourth quarter of 2025 (all comparisons to fourth quarter of 2024): Net premiums earned decreased 4.1% to $226.9 millionCombined ratio of 96.3%, compared to 92.9%Net income of $17.2 million, or 47 cents per diluted Class A share, compared to $24.0 million, or 70 cents per diluted Class A shareNet i...
- Jonathan Moreland
PMT PENNYMAC MORTGAGE INVESTMENT TRUST
TCBI TEXAS CAPITAL BANCSHARES INC.
SXI STANDEX INTERNATIONAL CORPORATION
PAYX PAYCHEX INC.
NBTB NBT BANCORP INC.
MNRO MONRO INC
LXRX LEXICON PHARMACEUTICALS INC.
LMAT LEMAITRE VASCULAR INC.
HUN HUNTSMAN CORPORATION
GME GAMESTOP CORP. CLASS A
FFIN FIRST FINANCIAL BANKSHARES INC
CR CRANE CO.
GAM GENERAL AMERICAN INVESTORS CO. INC.
ENPH ENPHASE ENERGY INC.
PCF PUTNAM HIGH INCOME SECURITIES FUND
AGYS AGILYSYS INC.
TYIA JOHNSON CONTROLS INTERNATIONAL PLC
LW LAMB WESTON HOLDINGS INC.
HWKN HAWKINS INC.
WDFC WD-40 COMPANY
HYT BLACKROCK CORPORATE HIGH YIELD FUND VI
CVCO CAVCO INDUSTRIES INC.
CRVS CORVUS PHARMACEUTICALS
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
ABT ABBOTT LABORATORIES
MVBF MVB FINANCIAL CORP
THM INTERNATIONAL TOWER HILL MINES LTD
NWFL NORWOOD FINANCIAL CORP.
ZIVO ZIVO BIOSCIENCE
SONO INC.
ANIX SONOS
ETON ANIXA BIOSCIENCES
AMTB ETON PHARMACEUTICALS
JYNT AMERANT BANCORP (A)
ALLY THE JOINT
CMTV GMAC LLC
ALXO COMMUNITY BANCORP INC. VT
AZYO ALX ONCOLOGY HOLDINGS
LUMN AZIYO BIOLOGICS
BST LUMEN TECHNOLOGIES INC.
LSF BLACKROCK SCIENCE AND TECHNOLOGY TRUST
VANI LAIRD SUPERFOOD INC
BOF VIVANI MEDICAL INC
WS WI BRANCHOUT FOOD INC.
MXF WORTHINGTON STEEL
GDV THE MEXICO FUND
PMN INC.
IP THE GABELLI DIVIDEND & INCOME TRUST
CVM PROMIS NEUROSCIENCES INC.
FEAM INTER PHARMA PUBLIC COMPANY LIMITED
BDSX CEL-SCI CORPORATION
MIGI 5E ADVANCED MATERIALS INC.
BIODESIX INC
MAWSON INFRASTRUCTURE GROUP INC
- Jonathan Moreland
MNRO MONRO INC
HUN HUNTSMAN CORPORATION
ASA ASA
ENPH ENPHASE ENERGY INC.
TYIA JOHNSON CONTROLS INTERNATIONAL PLC
HYT BLACKROCK CORPORATE HIGH YIELD FUND VI
CVCO CAVCO INDUSTRIES INC.
ETON ETON PHARMACEUTICALS
LUMN LUMEN TECHNOLOGIES INC.
ZIP ZIPRECRUITER
TMC INC.
TBBK TMC THE METALS CO INC
LSF THE BANCORP
PMN INC.
GF LAIRD SUPERFOOD INC
PROMIS NEUROSCIENCES INC.
THE NEW GERMANY FUND
INC.
HCI Group Sets Fourth Quarter and Full Year 2025 Earnings Call for Wed...
HCI Group Sets Fourth Quarter and Full Year 2025 Earnings Call for Wednesday, February 25, 2026, at 4:45 p.m. ET TAMPA, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- (NYSE: HCI) will hold a conference call on Wednesday, February 25, 2026, at 4:45 p.m. Eastern Time to discuss results for the fourth quarter and full year ended December 31, 2025. Financial results will be issued in a press release the same day after the close of the market. HCI management will host the presentation, followed by a question-and-answer period. Interested parties can listen to the live presentation by dialing the l...
Donegal Group Inc. Announces Release Date for Fourth Quarter and Full-...
Donegal Group Inc. Announces Release Date for Fourth Quarter and Full-Year 2025 Results MARIETTA, Pa., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Donegal Group Inc. (NASDAQ:DGICA) and (NASDAQ:DGICB) announced today that it plans to release its results for fourth quarter and full year ended December 31, 2025, on Thursday, February 19, 2026, before the opening of regular trading on the NASDAQ Stock Market. The Company will provide a supplemental investor presentation in the Investors section of its website at , concurrently with its earnings press release. At approximately 8:30 am ET on Thursday, F...
HCI Group Declares Quarterly Cash Dividend
HCI Group Declares Quarterly Cash Dividend TAMPA, Fla., Jan. 16, 2026 (GLOBE NEWSWIRE) -- The board of directors of HCI Group, Inc. (NYSE: HCI) has declared a regular quarterly cash dividend in the amount of 40 cents per common share. The dividend is scheduled to be paid March 20, 2026 to shareholders of record at the close of business February 20, 2026. About HCI Group, Inc. HCI Group, Inc. is a holding company with two distinct operating units. The first unit includes four top-performing insurance companies, a captive reinsurance company, and operations in claims management and real e...
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle...
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC) BioAtla will receive an initial $5 million for general operating and Phase 3 clinical trial expenses to advance Oz-V in 2L+ OPSCC with the remaining $35 million anticipated to close in Q1 2026.BioAtla to retain 65% ownership of Oz-V across all solid tumor indications after completion of the SPV transaction.BioAtla will lead Phase 3 trial execution for Oz-V in OPSCC through data readout...
Donegal Group Inc. Announces Quarterly Dividend
Donegal Group Inc. Announces Quarterly Dividend MARIETTA, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Donegal Group Inc. (NASDAQ:DGICA) and (NASDAQ:DGICB) reported today that its board of directors declared a regular quarterly cash dividend of $0.1825 per share of the Company’s Class A common stock and $0.165 per share of the Company’s Class B common stock. The dividends are payable on February 17, 2026 to stockholders of record as of the close of business on February 3, 2026. About Donegal Group Inc. Donegal Group Inc. is an insurance holding company whose insurance subsidiaries and affilia...
BioAtla Enters into Agreements for up to $22.5 Million Flexible Financ...
BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing These agreements are designed to be a flexible financing solution to support operations while finalizing a strategic partnershipCompany is in advanced stages to finalize a strategic transaction with a potential partner, and it remains on track to complete the transaction by year endThese agreements ensure BioAtla can maintain operational momentum while completing that process SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the devel...
BioAtla Reports Third Quarter 2025 Financial Results and Highlights Re...
BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress Company achieved FDA alignment on Phase 3 Oz-V trial for the treatment of 2L+ OPSCC, which will evaluate dual primary endpoints with potential of achieving accelerated approval followed by full approvalCompany is in advanced stages to finalize a strategic transaction with a potential partner and we remain on track to complete the transaction by year endBA3182 trial in advanced adenocarcinomas is currently ongoing and evaluating various dosing and treatment schedules with a readout expected in the first half ...
Huntsman Corp: 1 director
A director at Huntsman Corp bought 29,762 shares at 8.155USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrat...
BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas — Mec-V demonstrates median OS of 21.5 months in patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma compared with approximately 12 months with approved agents — Mec-V safety profile as monotherapy, and in combination with anti-PD-1 antibody, was manageable and consistent with conditional binding of the AXL target restricted to the tumor microenvironment SAN DIEGO, Nov. 07...
HCI Group Reports Third Quarter 2025 Results
HCI Group Reports Third Quarter 2025 Results TAMPA, Fla., Nov. 06, 2025 (GLOBE NEWSWIRE) -- HCI Group, Inc. (NYSE:HCI), reported pre-tax income of $90.6 million and net income of $67.9 million for the third quarter of 2025 compared with pre-tax income of $14.1 million and net income of $9.4 million for the third quarter of 2024. Net income after noncontrolling interests was $65.5 million compared with $5.7 million in the third quarter of 2024. Diluted earnings per share were $4.90 in the third quarter of 2025, compared with $0.52 in the third quarter of 2024. Management Commentary“This w...
BioAtla to Announce Third Quarter 2025 Financial Results and Provide B...
BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025 SAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, November 13, 2025 at 4:30 p.m. ET to discuss its financial results for the third quarter ended September 30, 2025 and provide business highlights. Conference C...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.